Plain-English translation of NCT06712121 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether venetoclax and decitabine, two medications, work better together to treat T-cell lymphoblastic leukemia or lymphoma that has come back or hasn't responded to earlier treatment. You would receive the medication in repeating cycles over about 3 months. The research team wants to see if this combination can help patients whose cancer is hard to treat.
T-cell leukemia and lymphoma are aggressive cancers that often come back or don't respond to standard chemotherapy. This trial exists because doctors need new treatment options for patients who haven't been helped by existing therapies, and early research suggests this medication combination may be promising.
You likely qualify if…
You likely don't qualify if…
You would take both medications in cycles: decitabine for 7 days followed by venetoclax for 3 weeks, repeating this pattern for up to 12 cycles (about 3 months total). You'll have regular visits to the hospital or clinic for blood tests, imaging, and bone marrow exams to see how you're responding. The research team will monitor you carefully for side effects and adjust your treatment as needed.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
South Korea